Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UNIPROT:P04626 (erbB-2)
 5,251 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

There were few, but conflicting, reports dealing with the clinical significance of c-erbB-2 in biliary tract cancer. We evaluated the expression of c-erbB-2 in normal epithelium of bile ducts (n = 46), gallbladder cancer (n = 11), carcinoma of the ampulla of Vater (n = 18), and intrahepatic cholangiocarcinoma (CC) (n = 18). c-erbB-2 protein is present in 63% (29/46) of surface epithelium in large and septal bile ducts, but not in peripheral small ducts. Overexpression of the gene product was found in 27.8% (5/18) of intrahepatic CC, 27.8% (5/18) of carcinoma of the ampulla of Vater, and 63.6% (7/11) of gallbladder cancer. But, there was no c-erbB-2 overexpression in the hyperplasia or atypical hyperplastic bile duct epithelium (p = 0.002). In terms of prognostic implication, expression of c-erbB-2 did not correlate to the histopathological grade (p = 0.60) and tumor stage (p = 0.63). The results indicate that c-erbB-2 protein may play some roles in physiology of normal bile ducts. Overexpression of the gene product occurs in one forth to about two thirds of carcinoma of biliary tract, and may be used as phenotypic marker for neoplastic transformation. However, the gene product may not be important in the aggressive behavior of tumor.
 ...
PMID:Significance of c-erbB-2 expression in normal and neoplastic epithelium of biliary tract. 764 25

The expression of oncogene products and growth factors (epidermal growth factor, transforming growth factor-beta, erbB-2, ras p 21, and c-myc) in gallbladder cancer and chronic cholecystitis was measured by immunohistochemical staining on paraffin-embedded serial sections. Expression of these products was graded according to staining intensity in an area of positively stained cells. This study reports the detection of oncogene products and growth factors in cholecystitis as well as in early and late gallbladder cancer. The multiexpression of oncogene products and growth factors was greater for both gallbladder cancer groups as compared with the cholecystitis group. The percentage of epidermal growth factor positivity diminished with increased proportion of interstitial tissue and, conversely, the percentage of transforming growth factor positivity increased with increased proportion of interstitial tissue. The proportion of ras positivity was significantly greater in both early and advanced cholecystic cancer as compared with cholecystitis, but also was considerable even for cholecystitis. These results suggest that various oncogenes may have significant roles in gallbladder cancer and that collagen synthesis is reduced by epidermal growth factor and enhanced by transforming growth factor-beta.
 ...
PMID:Expression of oncogene products and growth factors in early gallbladder cancer, advanced gallbladder cancer, and chronic cholecystitis. 808 75

Forty-three cases of gallbladder cancer were investigated for c-erbB-2 gene amplification and c-erbB-2 protein over-expression using a combined polymerase chain reaction (PCR) and immunohistochemical approach. Thirty out of 43 cases (69.6%) demonstrated c-erbB-2 gene amplification, the positive rates being 50% and 77.4% for twelve early cancers and thirty-one advanced cancers, respectively (P < 0.05). However, there was no statistically significant correlation between c-erbB-2 gene amplification and histologic grade of differentiation or lymph node metastasis. Fourteen out of 43 cases (32.6%) showed positive immunoreactivity reflecting c-erbB-2 protein over-expression but again no statistically significant correlation was found with grade of differentiation, invasion or lymph node metastasis. Neither the c-erbB-2 gene nor the protein revealed any close relation to prognosis. In contrast, histopathologic findings for histologic grade of differentiation, invasion grade and lymph node metastasis showed good correlations to prognosis and between themselves. In conclusion, while c-erbB-2 gene and protein in gallbladder cancers might be related to invasiveness, they are not applicable as predictive factors for prognosis.
 ...
PMID:An immunohistochemical and molecular biological study of c-erbB-2 amplification and prognostic relevance in gallbladder cancer. 810 75

c-erbB-2, proto-oncogene is amplified and overexpressed in a number of human adenocarcinomas. Overexpression of c-erbB-2 is indicated as a worse prognostic factor and associated with neoplastic progression in various organs. To investigate the therapeutic effect of Trastuzumab in gallbladder cancer, we studied HER-2/neu expression in 43 primary tumors, 12 metastatic lymph nodes and two liver metastasis, using the Hercep test. Among primary tumors, strong (3+) immunohistochemical intensity was found in two cases (4.7%), weak (2+) in two (4.7%) and negative (1+) (2.3%) in one case. This positivity rate was distinctly lower than those in previous reports. There was no tendency between clinicopathologic characteristics and HER-2 positivity in the primary gallbladder. Among 12 metastatic lymph nodes, only one specimen showed 2+ positivity where the primary lesion revealed 3+ intensity of HER-2. In two liver metastatic lesions, the expression of HER-2 was not found. Our study implied that Trastzumab may not contribute to improvement in treatment of gallbladder cancer. However, there may be a therapeutic possibility for cases with lymph node recurrence overexpressing c-erbB-2.
 ...
PMID:Gallbladder cancers rarely overexpress HER-2/neu, demonstrated by Hercep test. 1501 Aug 78